StockData
Korsana Biosciences, Inc. logo

Korsana Biosciences, Inc. (KRSA) stock

KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30498% above fair value
$32.50−0.18 (-0.55%)

Close on Nov 17, 2026Market cap $152.14MP/E –Yield –

Korsana Biosciences operating margin

Operating margin is operating income as a percentage of revenue.

Korsana Biosciences's operating margin for the twelve months ending Jun 30, 2026 was -359.2%. For fiscal 2025 it was -239.8%, against -181.4% the year before. The highest annual figure on record is -181.4% in fiscal 2024.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-239.8%−58.4
FY2024Dec 31, 2024-181.4%+6061.0
FY2022Dec 31, 2022-6242.4%−4842.2
FY2021Dec 31, 2021-1400.2%+2139.2
FY2020Dec 31, 2020-3539.4%−765.1
FY2019Dec 31, 2019-2774.3%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2025Dec 31, 2025-81.8%−109.6
Q3 FY2025Sep 30, 2025-115.0%+466.5
Q2 FY2025Jun 30, 2025-1797.8%+2592.0
Q1 FY2025Mar 31, 2025-1798.8%+27.4
Q4 FY2024Dec 31, 202427.8%+2717.9
Q3 FY2024Sep 30, 2024-581.4%+2661.4
Q2 FY2022Jun 30, 2022-4389.9%−3850.7
Q1 FY2022Mar 31, 2022-1826.2%+19778.7
Q4 FY2021Dec 31, 2021-2690.1%+11764.1
Q3 FY2021Sep 30, 2021-3242.8%+2202.2
Q2 FY2021Jun 30, 2021-539.2%+2087.2
Q1 FY2021Mar 31, 2021-21604.8%−19574.4
Q4 FY2020Dec 31, 2020-14454.1%−12659.0
Q3 FY2020Sep 30, 2020-5445.0%−3441.0
Q2 FY2020Jun 30, 2020-2626.4%−596.1
Q1 FY2020Mar 31, 2020-2030.5%–
Q4 FY2019Dec 31, 2019-1795.1%–
Q3 FY2019Sep 30, 2019-2004.0%–
Q2 FY2019Jun 30, 2019-2030.3%–

More Korsana Biosciences figures

See a number that looks wrong?